T1	CHEM 1 10	Lidocaína
#1	AnnotatorNotes T1	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T2	PROC 29 65	tratamiento del dolor posmastectomía
T3	PROC 158 194	tratamiento del dolor postoperatorio
T4	DISO 174 194	dolor postoperatorio
#2	AnnotatorNotes T4	C0030201; Pain, Postoperative; Sign or Symptom
T5	PROC 201 212	mastectomía
#3	AnnotatorNotes T5	C0024881; Mastectomy; Therapeutic or Preventive Procedure
T6	PROC 752 761	infundida
#4	AnnotatorNotes T6	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T7	CHEM 345 354	lidocaína
#5	AnnotatorNotes T7	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T8	PROC 392 403	mastectomía
#6	AnnotatorNotes T8	C0024881; Mastectomy; Therapeutic or Preventive Procedure
T9	CHEM 443 451	opiáceos
#7	AnnotatorNotes T9	C0242402; Opioids; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance | C0376196; Opiates; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance
T10	PROC 945 968	índice de masa corporal
#8	AnnotatorNotes T10	C0005893; Body mass index procedure; Diagnostic Procedure | C3698309; Measurement of body mass index; Health Care Activity
T11	CHEM 706 715	lidocaína
#9	AnnotatorNotes T11	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T12	PROC 801 812	mastectomía
#10	AnnotatorNotes T12	C0024881; Mastectomy; Therapeutic or Preventive Procedure
T13	PROC 818 835	anestesia general
#11	AnnotatorNotes T13	C0002915; General Anesthesia; Therapeutic or Preventive Procedure
T14	PROC 860 867	placebo
#12	AnnotatorNotes T14	C0032042; Placebos; Therapeutic or Preventive Procedure
T15	PROC 978 1001	intervención quirúrgica
#13	AnnotatorNotes T15	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T16	CHEM 1017 1025	opiáceos
#14	AnnotatorNotes T16	C0242402; Opioids; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance | C0376196; Opiates; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance
T17	CHEM 1060 1068	opiáceos
#15	AnnotatorNotes T17	C0242402; Opioids; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance | C0376196; Opiates; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance
T18	CHEM 1104 1113	lidocaína
#16	AnnotatorNotes T18	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T19	PROC 1121 1128	placebo
#17	AnnotatorNotes T19	C0032042; Placebos; Therapeutic or Preventive Procedure
T20	CHEM 1200 1209	lidocaína
#18	AnnotatorNotes T20	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T21	PROC 1240 1247	placebo
#19	AnnotatorNotes T21	C0032042; Placebos; Therapeutic or Preventive Procedure
T22	CHEM 1333 1342	lidocaína
#20	AnnotatorNotes T22	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T23	PROC 1345 1352	placebo
#21	AnnotatorNotes T23	C0032042; Placebos; Therapeutic or Preventive Procedure
T24	PROC 1409 1433	procedimiento quirúrgico
#22	AnnotatorNotes T24	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T25	CHEM 1540 1549	lidocaína
#23	AnnotatorNotes T25	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T26	PROC 1650 1661	mastectomía
#24	AnnotatorNotes T26	C0024881; Mastectomy; Therapeutic or Preventive Procedure
T27	PROC 1714 1721	placebo
#25	AnnotatorNotes T27	C0032042; Placebos; Therapeutic or Preventive Procedure
T28	CHEM 1772 1780	opiáceos
#26	AnnotatorNotes T28	C0242402; Opioids; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance | C0376196; Opiates; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance
T29	CHEM 1847 1856	lidocaína
#27	AnnotatorNotes T29	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T30	PROC 1909 1931	regímenes terapéuticos
#28	AnnotatorNotes T30	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T31	DISO 45 65	dolor posmastectomía
#29	AnnotatorNotes T31	C0406845; Post-mastectomy pain; Sign or Symptom
T32	PROC 67 126	ensayo clínico aleatorizado, encubierto, placebo controlado
#30	AnnotatorNotes T32	C0206034; Clinical Trials, Randomized; Research Activity + C0150108; Blinded; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product
T33	PROC 642 701	ensayo clínico aleatorizado, encubierto, placebo controlado
#31	AnnotatorNotes T33	C0206034; Clinical Trials, Randomized; Research Activity + C0150108; Blinded; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product
T34	ANAT 960 968	corporal
#32	AnnotatorNotes T34	C0460148; Human body structure; Anatomical Structure | C1318419; Entire human body; Anatomical Structure
T35	DISO 1161 1166	dolor
#33	AnnotatorNotes T35	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T37	DISO 1484 1489	dolor
#34	AnnotatorNotes T37	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T38	PROC 1672 1681	analgesia
#35	AnnotatorNotes T38	C3202977; Analgesia; Therapeutic or Preventive Procedure
T39	Route 11 22	intravenosa
#36	AnnotatorNotes T39	C1522726; Intravenous Route of Drug Administration; Functional Concept
T41	Time 180 194	postoperatorio
#37	AnnotatorNotes T41	C0032790; Postoperative Period; Temporal Concept
T42	Route 355 366	intravenosa
#38	AnnotatorNotes T42	C1522726; Intravenous Route of Drug Administration; Functional Concept
T43	LIVB 370 379	pacientes
#39	AnnotatorNotes T43	C0030705; Patients; Patient or Disabled Group
T44	Time 425 439	postoperatorio
#40	AnnotatorNotes T44	C0032790; Postoperative Period; Temporal Concept
T46	Route 716 727	intravenosa
#41	AnnotatorNotes T46	C1522726; Intravenous Route of Drug Administration; Functional Concept
T47	Dose 731 751	una dosis de 3 mg/kg
T49	Duration 765 773	una hora
T50	LIVB 781 788	mujeres
#42	AnnotatorNotes T50	C0043210; Woman; Population Group
T51	LIVB 841 849	paciente
#43	AnnotatorNotes T51	C0030705; Patients; Patient or Disabled Group
T52	Neg_cue 872 880	excluida
T54	Time 1032 1046	postoperatorio
#44	AnnotatorNotes T54	C0032790; Postoperative Period; Temporal Concept
T55	LIVB 1074 1083	pacientes
#45	AnnotatorNotes T55	C0030705; Patients; Patient or Disabled Group
T57	DISO 1386 1391	dolor
#46	AnnotatorNotes T57	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T58	Duration 1392 1396	24 h
T59	LIVB 1464 1473	pacientes
#47	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T61	Route 1550 1561	intravenosa
#48	AnnotatorNotes T61	C1522726; Intravenous Route of Drug Administration; Functional Concept
T62	Dose 1565 1585	una dosis de 3 mg/kg
T64	Duration 1616 1624	una hora
T65	Time 1631 1646	transoperatorio
#49	AnnotatorNotes T65	C0021891; Intraoperative Period; Temporal Concept | C0456904; Intraoperative; Temporal Concept
T66	Neg_cue 1662 1664	no
T67	Duration 1725 1742	las primeras 24 h
T72	Route 1857 1868	intravenosa
#50	AnnotatorNotes T72	C1522726; Intravenous Route of Drug Administration; Functional Concept
T73	LIVB 1872 1881	pacientes
#51	AnnotatorNotes T73	C0030705; Patients; Patient or Disabled Group
T36	PHYS 1170 1179	despertar
#52	AnnotatorNotes T36	C0442696; Waking; Physiologic Function
T40	Time 1276 1290	postanestésica
T45	LIVB 531 544	seres humanos
#53	AnnotatorNotes T45	C0086418; Homo sapiens; Human
A1	Assertion T51 Negated
A2	Assertion T38 Negated
R1	Has_Route_or_Mode Arg1:T1 Arg2:T39	
R2	Used_for Arg1:T1 Arg2:T2	
R3	Overlap Arg1:T4 Arg2:T41	
R4	Causes Arg1:T5 Arg2:T4	
T48	Observation 321 338	efecto analgésico
#54	AnnotatorNotes T48	C0948482; Analgesic effect; Finding
R6	Has_Route_or_Mode Arg1:T7 Arg2:T42	
R7	Causes Arg1:T7 Arg2:T48	
R8	Experiences Arg1:T43 Arg2:T48	
R9	Experiences Arg1:T43 Arg2:T7	
R10	Experiences Arg1:T43 Arg2:T8	
R11	Overlap Arg1:T9 Arg2:T44	
R12	Experiences Arg1:T43 Arg2:T9	
R13	Before Arg1:T8 Arg2:T9	
R14	Has_Route_or_Mode Arg1:T11 Arg2:T46	
R15	Has_Dose_or_Strength Arg1:T11 Arg2:T47	
R16	Experiences Arg1:T45 Arg2:T11	
R17	Has_Duration_or_Interval Arg1:T6 Arg2:T49	
R18	Used_for Arg1:T11 Arg2:T6	
R19	Before Arg1:T13 Arg2:T12	
R21	Used_for Arg1:T11 Arg2:T13	
R22	Experiences Arg1:T50 Arg2:T11	
R23	Experiences Arg1:T50 Arg2:T12	
R24	Negation Arg1:T52 Arg2:T51	
R25	Experiences Arg1:T51 Arg2:T14	
R26	Location_of Arg1:T34 Arg2:T10	
R27	Overlap Arg1:T16 Arg2:T54	
R28	Before Arg1:T15 Arg2:T16	
R29	Experiences Arg1:T55 Arg2:T17	
R30	Experiences Arg1:T55 Arg2:T18	
R31	Experiences Arg1:T55 Arg2:T19	
R32	Overlap Arg1:T35 Arg2:T36	
R35	Overlap Arg1:T35 Arg2:T40	
R38	Overlap Arg1:T57 Arg2:T58	
R39	Causes Arg1:T24 Arg2:T57	
R40	Experiences Arg1:T59 Arg2:T37	
R41	Experiences Arg1:T59 Arg2:T57	
R42	Experiences Arg1:T59 Arg2:T24	
R43	Overlap Arg1:T37 Arg2:T58	
R44	Has_Route_or_Mode Arg1:T25 Arg2:T61	
R45	Has_Dose_or_Strength Arg1:T25 Arg2:T62	
R46	Has_Duration_or_Interval Arg1:T25 Arg2:T64	
R47	Overlap Arg1:T25 Arg2:T65	
R50	Negation Arg1:T66 Arg2:T38	
R51	Has_Duration_or_Interval Arg1:T38 Arg2:T67	
R52	Has_Duration_or_Interval Arg1:T27 Arg2:T67	
T53	Neg_cue 1745 1747	no
T56	Observation 1748 1780	disminuyó el consumo de opiáceos
A3	Assertion T56 Negated
R53	Negation Arg1:T53 Arg2:T56	
T60	Spec_cue 1795 1818	no puede ser descartado
T63	Observation 1822 1840	efecto beneficioso
A4	Assertion T63 Speculated
R54	Speculation Arg1:T60 Arg2:T63	
R55	Before Arg1:T25 Arg2:T56	
R56	Before Arg1:T25 Arg2:T28	
R57	Before Arg1:T29 Arg2:T63	
R58	Has_Route_or_Mode Arg1:T29 Arg2:T72	
R59	Experiences Arg1:T73 Arg2:T29	
R60	Experiences Arg1:T73 Arg2:T63	
R61	Experiences Arg1:T73 Arg2:T30	
R62	Before Arg1:T26 Arg2:T28	
R63	Before Arg1:T18 Arg2:T17	
R64	Before Arg1:T19 Arg2:T17	
R67	Causes Arg1:T24 Arg2:T37	
R5	Overlap Arg1:T3 Arg2:T41	
#55	AnnotatorNotes T63	C4049461; Unexpected beneficial therapeutic response; Finding (?)
A5	Experiencer T43 Patient
A6	Experiencer T45 Patient
A7	Experiencer T50 Patient
A8	Experiencer T51 Patient
A9	Experiencer T55 Patient
A10	Experiencer T59 Patient
A11	Experiencer T73 Patient
